NewsBenzinga凯文纳治疗宣布KYSA-8试验中Miv-Cel在强直人综合症患者的一年顶线数据,以及KYSA-6第二阶段试验中患有全身性重症肌无力患者的长期跟踪顶线数据;顶线持久性数据强化单剂Miv-Cel释放患者免于终身疾病负担和慢性免疫治疗的潜力,进一步突显Miv-Cel的差异化结构。 凯文纳治疗宣布KYSA-8试验中Miv-Cel在强直人综合症患者的一年顶线数据,以及KYSA-6第二阶段试验中患有全身性重症肌无力患者的长期跟踪顶线数据;顶线持久性数据强化单剂Miv-Cel释放患者免于终身疾病负担和慢性免疫治疗的潜力,进一步突显Miv-Cel的差异化结构。 Benzinga 2026.09.24 10:05 (GMT+0) Open on Benzinga Other news StoneX Maintains Buy on Rivian Automotive, Lowers Price Target to $20 Amer Sports Unleashes $1 Billion Buyback, Raises 2026 Outlook EXCLUSIVE: Tesla Still Rules Leveraged ETFs, but Anthropic IPO and Micron’s Rise Signal What’s Next StoneX Reiterates Hold on iQIYIto Hold StoneX Maintains Buy on Baidu, Lowers Price Target to $125 Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide
Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide